Ann: Quarterly Report & Appendix 4C - 31 December 2014, page-4

So as I see it, the Medivet business continues to consume cash in terms of restructuring but more exciting, is the use for sales and marketing resources and R&D. The announcement about the dog cancer vaccine is exciting and hopefully we can find out more about other projects. The big question will be when will they be commercialised? (Although everyone else seems to gets rated highly for research alone when Medivet has both research and revenue!)
The revenue line continues to impress and I am guessing (reading between the lines) that the bulk of this growth if not all has come from the Human Health business. As I said before, it seems crazy to me that the previous management were downplaying the prospects for this part of the business when it would now seem to be a hidden gem. It will be good to find out more about future product developments too. MLA should be able to grow its share given the size of the market. Also following on from Wegian, the health care market should continue to grow at better than GDP given the ageing population and increasing demand for health care.
Its pleasing to see MLA communicating more about the business. Ellis and Hancox are driving this business in the right direction. Can't wait to see the half year report and hopefully get more details on segment performance.
Expect big upside to this stock!